Syringe drivers and subcutaneous sites: A review

European Journal of Palliative Care

Volumn 13, Issue 4, 2006, Pages 138-141

  Graham, Fiona ^a,b  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746590224     PISSN: 13522779     EISSN: 14790793     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Expert Working Group of the European Association for Palliative Care. Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823-826.
2. www.palliativedrugs.com (last accessed 5/5/06)
3. Haller JS. Hypodermic medication. N Y State J Med 1981; 81(11): 1671-1679.
4. Mogey GA. Centenary of hypodermic injection. BMJ 1953; 2: 1180-1185.
5. Howard-Jones N. The origins of hypodermic medication. Sci Am 1971; 224: 96-102.
6. Hunter C. Hypodermical treatment of disease. Lancet 1863; 2: 675-676.
7. Propper RD, Cooper B, Rufo, R et al. Continuous subcutaneous administration of Deferoxamine in patients with iron overload. New Engl J Med 1977; 297(8): 418-423.
8. Graham F, Clark D. The syringe driver and the subcutaneous route in palliative care: the inventor, the history and the implications. J Pain Symptom Manage 2005; 29(1): 32-40.
9. Russell PSB. Analgesia in terminal malignant disease. BMJ 1979; 1:1561.
10. Edwards S. Evaluating syringe drivers. Nurs Times 1992; 88(3): 46-47.
11. Cools HJ, Berkhout AM, De Bock GH. Subcutaneous morphine infusion by syringe driver for terminally ill patients. Age Ageing 1996; 25: 206-208.
12. Morgan M, Evans N. A small observational study of the longevity of syringe driver sites in palliative care. Int J Pall Nurse 2004; 10(8): 405-412.
13. Adams F, Cruz L, Deachman MJ, Zamora E. Focal subdermal toxicity with subcutaneous opioid infusions in patients with cancer pain. J Pain Symptom Manage 1989; 4: 31-33.
14. Brenneis C, Michaud M, Bruera E, MacDonald RN. Local toxicity during subcutaneous infusion of narcotics (SCIN). A prospective study. Cancer Nurs 1987; 10: 172-176.
15. Dickman A, Schneider J, Varga J. The Syringe Driver: Continuous subcutaneous infusions in palliative care, 2nd edn. Oxford: Oxford University Press, 2005.
16. Sykes NP, Oliver DJ. Isotonic methotrimeprazine by continuous infusion in terminal care. Lancet 1987; 1: 393-394.
17. Matthew P, Storey P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. J Pain Symptom Manage 1999; 18(1): 49-52.
18. Oliver DJ. Syringe drivers in palliative care: a review. Palliat Med 1988; 2: 21-26.
19. Lichter I, Hunt E. Drug combinations in syringe drivers. NZ Med J 1995; 108: 224-226.
20. Grassby PF, Hutchings L. Drug combinations in syringe drivers: the compatibility and stability of diamorphine with cyclizine and haloperidol. Palliat Med 1997; 11: 217-224.
21. www.pallcare.info/ (last accessed 5/5/06)
22. Wright BM, Callan K. Slow drug infusions using a portable syringe driver. BMJ 1979; 2: 528.
23. Youssef MS, Atkinson RE. Comparison of Teflon cannulas and metal needles for subcutaneous infusion in terminal care: a pilot study. BMJ 1990; 300: 847.
24. Ventafridda V, Spoldi E, Caraceni A et al. The importance of continuous subcutaneous morphine administration for cancer pain control. Pain Clin 1986; 1: 47-55.
25. Macmillan K, Bruera E, Kuehn N, Selmser P, Macmillan A. A prospective comparison study between a butterfly needle and a Teflon cannula for subcutaneous narcotic administration. J Pain Symptom Manage 1994; 9(2): 82-84.
26. Currow D, Cooney N. Comparison of metal versus Vialon subcutaneous catheters in a palliative care setting. Palliat Med 1994; 8: 333-336.
27. Dawkins L, Britton D, Johnson I, Higgins B, Dean T. A randomized trial of winged Vialon cannulae and metal butterfly needles. Int J Palliat Nurs; 2000; 6(3): 110-116.
28. Ross JR, Saunders Y, Cochrane M, Zeppetella G. A prospective, within-patient comparison between metal butterfly needles and Teflon cannulae in subcutaneous infusion of drugs to terminally ill hospice patients. Palliat Med 2002; 16: 13-16.
29. Torre MC. Subcutaneous infusion: non-metal cannulae vs metal butterfly needles. Brit J Comm Nurs 2002, 7970: 365-369.
30. www.bd.com/infusion/products/fbsti.asp (last accessed 5/5/06)
31. Twycross R, Wilcock A. Symptom Management in advanced cancer, 3rd edn. Oxford: Radcliffe Medical Press, 2001: 384-385.
32. Twycross R, Wilcock A, Charlesworth S, Dickman A. Palliative Care Formulary, 2nd edn. Oxford. Radcliffe Medical Press, 2002: 301.
33. Dickman A, Littlewood C, Varga J. The Syringe Driver: Continuous subcutaneous infusions in palliative care. Oxford: Oxford University Press, 2002: 8.
34. Flowers C, McLeod F. Diluent of choice for subcutaneous infusion: a survey of Australian practice. Int J Palliat Nurs 2005; 11: 54-60.
35. Nicholson H. The success of the syringe driver. Nurs, Times 1986; 82(28): 42-55.
36. Mitten T. Subcutaneous drug infusions: a review of problems and solutions. Int J Palliat Nurs 2001; 7(2): 75-85.
37. Regnard C, Newbury A. Pain and the portable syringe pump. Nurs Times 1983; 79(26): 25-28.
38. Redmond L, Charles M, Bowman J, Treston P. The effect of dexamethsone on the longevity of syringe driver subcutaneous sites in palliative care patients. Med J Aust 2003; 178(10): 486-489.